{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:42:48Z","timestamp":1772138568135,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Particularly because the risk of harm cannot be safely excluded, the use of phosphate binders in chronic kidney disease (CKD) patients demands caution. Yet, the clinical inertia concerning phosphate burden is unjustified. Inorganic, phosphate esters added to preserve food represent an important component of dietary phosphate load. These compounds are easily absorbable and have a measurable effect on serum phosphate, and therefore their use should be avoided in CKD patients. The ongoing CKD Optimal management with Binders and NicotinamidE (COMBINE) study, applying chelation by phosphate binders and intestinal Na\u2013P channel blockade by nicotinamide, will establish whether this combination may effectively reduce serum phosphate and fibroblast growth factor 23 in pre-dialysis CKD patients and produce improvements in surrogate measures of cardiovascular and renal damages. On the other hand, the ANSWER study will ascertain whether phosphate reduction by sevelamer carbonate may have an antiproteinuric effect in CKD patients with residual proteinuria despite effective blockade of the renin\u2013angiotensin system. At this stage of knowledge, the use of phosphate binders in pre-dialysis CKD patients cannot be recommended. Ongoing studies will tell us whether the application of these drugs may have beneficial health effects in CKD patients at the pre-dialysis stage.<\/jats:p>","DOI":"10.1093\/ndt\/gfv404","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:16:46Z","timestamp":1450397806000},"page":"196-199","source":"Crossref","is-referenced-by-count":1,"title":["Moderator's view: Phosphate binders in chronic kidney disease patients: a clear \u2018No\u2019 at the moment, but stay tuned"],"prefix":"10.1093","volume":"31","author":[{"given":"Carmine","family":"Zoccali","sequence":"first","affiliation":[{"name":"Ospedali Riuniti 1 CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases , , Reggio Calabria ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"Ospedali Riuniti 1 CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases , , Reggio Calabria ,","place":["Italy"]},{"name":"Ospedali Riuniti 2 Nephrology, Hypertension and Renal Transplantation Unit , , Reggio Calabria ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"2025102312481632700_GFV404C1","volume-title":"Sackett Clinical Epidemiology","author":"Sackett","year":"1985","edition":"1st edn"},{"key":"2025102312481632700_GFV404C2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/sdi.12416","article-title":"Phosphate binders and clinical outcomes in patients with stage 5D chronic kidney disease","volume":"28","author":"Zoccali","year":"2015","journal-title":"Semin Dial"},{"key":"2025102312481632700_GFV404C4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/ndt\/gfn238","article-title":"European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP)","volume":"23","author":"Zoccali","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481632700_GFV404C5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481632700_GFV404C6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archpedi.1941.02000110069006","article-title":"Journal of hypertension","volume":"61","author":"Freeman","year":"1942","journal-title":"Am J Dis Child"},{"key":"2025102312481632700_GFV404C7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2215\/CJN.05060610","article-title":"Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients","volume":"6","author":"Winkelmayer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2215\/CJN.05130610","article-title":"Prevention and control of phosphate retention\/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?","volume":"6","author":"Martin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.ki.5002397","article-title":"The valuable contribution of observational studies to nephrology","volume":"72","author":"Jager","year":"2007","journal-title":"Kidney Int"},{"key":"2025102312481632700_GFV404C10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition","volume":"22","author":"Zoccali","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1681\/ASN.2012060569","article-title":"Phosphate binders in CKD: bad news or good news?","volume":"23","author":"Drueke","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1681\/ASN.2014010104","article-title":"Proteinuria increases plasma phosphate by altering its tubular handling","volume":"26","author":"de Seigneux","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C14","first-page":"184","article-title":"Pro: Should phosphate binders be used in chronic kidney disease stage 3\u20134?","volume":"31","author":"Bellasi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481632700_GFV404C15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2015","journal-title":"Arch Intern Med"},{"key":"2025102312481632700_GFV404C16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025102312481632700_GFV404C17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/ndt\/gfv406","article-title":"Con: Phosphate binders in chronic kidney disease","volume":"31","author":"Kestenbaum","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312481632700_GFV404C19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025102312481632700_GFV404C20","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int"},{"key":"2025102312481632700_GFV404C21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-And\u00eda","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312481632700_GFV404C22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2025102312481632700_GFV404C23","first-page":"49","article-title":"Phosphate additives in food: a health risk","volume":"109","author":"Ritz","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"2025102312481632700_GFV404C24"},{"key":"2025102312481632700_GFV404C25","author":"Sevelamer in Proteinuric CKD"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/31\/2\/196\/7429942\/gfv404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/31\/2\/196\/7429942\/gfv404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:43Z","timestamp":1761238123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/31\/2\/196\/2460106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,12,17]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfv404","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726022265.793515576","asserted-by":"object"}]},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2015,12,17]]}}}